With Kolltan, Kinase Veteran Schlessinger Turns To Antibodies
This article was originally published in Start Up
Executive Summary
Joseph Schlessinger’s insights into receptor tyrosine kinases (RTKs) led to small-molecule treatments and huge success at Sugen and Plexxikon. Schlessinger’s latest venture, Kolltan Pharmaceuticals, had little trouble raising $75 million, but powering up a pipeline of antibodies to target novel RTKs has proven more challenging.
You may also be interested in...
Kolltan Approaching First IND Submission For RTK-Targeted Oncology Drug Candidate
Having raised about $75 million in venture funding since its 2007 inception, Kolltan Pharmaceuticals is getting closer to the clinic with novel oncology candidates targeting receptor tyrosine kinases.
Overcoming Disaster: What Biotechs Do When A Lead Asset Fails
Drug candidates fail at an alarming rate. For biotechs that seemingly have their entire future - and tens of millions of investor dollars - tied up in one compound or one clinical trial, failure of a lead asset can mean certain, sudden death. Meet four small companies that had another plan.
With A New CSO, Bristol-Myers Squibb Doubles Down On Immuno-Oncology
BMS’ strategy for the complex, highly competitive immuno-oncology field. A Q&A with the company’s new R&D chief, lung cancer specialist Thomas Lynch, MD.
Need a specific report? 1000+ reports available
Buy Reports